Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

ClinicalTrials.gov ID: NCT03050151

Public ClinicalTrials.gov record NCT03050151. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).

Study identification

NCT ID
NCT03050151
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
176 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 27, 2017
Primary completion
Nov 13, 2017
Completion
Feb 11, 2018
Last update posted
Jul 31, 2018

2017 – 2018

United States locations

U.S. sites
37
U.S. states
19
U.S. cities
35
Facility City State ZIP Site status
Regeneron Investigational Site Birmingham Alabama 35205
Regeneron Investigational Site Birmingham Alabama 35209
Regeneron Investigational Site Fort Smith Arkansas 72916
Regeneron Investigational Site Long Beach California 90808
Regeneron Investigational Site Los Angeles California 90025
Regeneron Investigational Site Murrieta California 92562
Regeneron Investigational Site Oceanside California 92056
Regeneron Investigational Site Orange California 92868
Regeneron Investigational Site Rolling Hills Estates California 90274
Regeneron Investigational Site Santa Monica California 90404
Regeneron Investigational Site Denver Colorado 80220
Regeneron Investigational Site Coral Gables Florida 33613
Regeneron Investigational Site Tampa Florida 33612
Regeneron Investigational Site Normal Illinois 61761
Regeneron Investigational Site Skokie Illinois 60077
Regeneron Investigational Site Indianapolis Indiana 46256
Regeneron Investigational Site Rockville Maryland 20850
Regeneron Investigational Site Plymouth Minnesota 55441
Regeneron Investigational Site Saint Joseph Missouri 64506
Regeneron Investigational Site Berlin New Jersey 08009
Regeneron Investigational Site Windsor New Jersey 08520
Regeneron Investigational Site Corning New York 14830
Regeneron Investigational Site Forest Hills New York 11375
Regeneron Investigational Site New York New York 10029
Regeneron Investigational Site High Point North Carolina 27262
Regeneron Investigational Site Raleigh North Carolina 27612
Regeneron Investigational Site Tulsa Oklahoma 74136
Regeneron Investigational Site Portland Oregon 97223
Regeneron Investigational Site Charleston South Carolina 29420
Regeneron Investigational Site Greer South Carolina 29650
Regeneron Investigational Site Bellaire Texas 77401
Regeneron Investigational Site Fort Worth Texas 76244
Regeneron Investigational Site San Antonio Texas 78213
Regeneron Investigational Site San Antonio Texas 78218
Regeneron Investigational Site Webster Texas 77598
Regeneron Investigational Site Norfolk Virginia 23502
Regeneron Investigational Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03050151, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2018 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03050151 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →